Clinical Trial Update: An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes [Phase 3]

View source ↗

Summary

This report updates a Phase 3 efficacy trial evaluating epoetin alfa for anemia in patients with myelodysplastic syndromes, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: COMPLETED